Effectiveness of Drug Eluting TACE in Primary HCC

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

EARLY_PHASE1

Total Enrollment

75 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-09-01

Study Completion Date

2020-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

the aim of this work to compare effectiveness of drug-eluting bead trans-arterial chemo-embolization and conventional trans-arterial chemo-embolization of hepatic cell carcinoma in the aspect of (Tumor response via m-RECIST criteria), (liver injury via Liver function tests and tumor markers) and (survival outcome) of patients treated in Assiut university .

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

DEB-TACE+HAIC vs. HAIC for Large HCC

NCT05263219

Unresectable Hepatocellular Carcinoma

RECRUITING PHASE3

The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma

NCT05862181

Advanced Hepatocellular Carcinoma (HCC)

UNKNOWN

Hepatocellular Carcinoma (HCC) Transarterial Chemoembolisation (TACE) +Axitinib

NCT01352728

Hepatocellular Carcinoma

COMPLETED PHASE2

Efficacy and Safety of Drug Eluting Beads TACE in Treatment of HCC in Egyptian Patients

NCT03007225

HepatoCellular Carcinoma

COMPLETED PHASE4

A Real-world Study of the Short-term Efficacy and Safety of E-TACE in Patients With Hepatocellular Carcinoma (HCC)

NCT06023147

Hepatocellular Carcinoma

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hepatocellular carcinoma (HCC) is the sixth most common cancer in the world and the third most common cause of cancer-related death .. With improved surveillance of patients with chronic liver disease and advances in imaging, more patients are diagnosed with early-stage HCC . For the treatment of early stage HCC, curative therapies including liver transplantation, hepatic resection, and radio frequency ablation (RFA) are recommended. Liver transplantation is the treatment option especially for patients with decompensated cirrhosis, but potential recipients outnumber donors. Hepatic resection is widely used as the main choice of treatment for resectable HCC. However, the risk of postoperative hepatic dysfunction often precludes surgery.

For unresectable patient, trans-arterial chemo-embolization (TACE) was the treatment of choice .

At 2014, Yang et al. compared the treatment effects of hepatic resection, RFA, and conventional TACE on long-term survival. It was found that the range of patients treated by TACE in clinical practice reported survivals widely range from 8-26% at 5-years. which was similar to that with hepatic resection and RFA in patients with single-nodule HCC of 3 cm or smaller without vascular invasion when the underlying liver status was balanced among the patients receiving each treatment. In addition, most of the patients initially treated with c-TACE achieved a complete response, which was one of the independent prognostic factors of survival, although some should receive repeated treatments. However, when c-TACE is used as an initial treatment, special care should be taken to obtain a complete response, and surveillance for tumor recurrence should be undertaken. These results are consistent with those of cohort studies demonstrating that TACE provided overall survival similar to hepatic resection in early-stage HCC .

Conventional (Lipiodol) TACE Base on technique with emulsified combination of chemotherapy such as Doxorubicin and Lipiodol administrate via arterial feeder.

Less in systemic chemotherapy and increase overall survival rate were the most concern in treatment but many studies reported side effects from conventional (Lipiodol) TACE significantly among an improvement of overall survival rate .

Conventional TACE may cause side effects because it can damage healthy cells as it kills cancer cells. Side effects can develop any time during, immediately after or a few days or weeks after chemotherapy . in addition to the patient needed frequent ablation after a short time .

The most commonly Side Effect of TACE is (Post embolization syndrome) which is a group of symptoms . include : fever, Right upper quadrant pain, nausea, vomiting and fatigue .

Other side effects may occur include bruising or bleeding at the catheter site, hair loss, abnormal liver functions, lung infections, gall bladder inflammation and tumor lysis syndrome .

Drug-eluting bead TACE is the new method of delivering chemotherapy during TACE which uses special beads that already have the chemotherapy drug in them . after these are injected into the arteries of the liver , they slowly sustained releasing the drug to treat the tumor .

The studies showed that TACE with (Hepasphere) less systemic side effect in patient than TACE with (Lipiodol) but no definite statistical difference in treatment and survival outcome.

This study compares effectiveness of those methods in treatment of Hepatocellular carcinoma in Assiut university

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatic Cell Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

drug eluting bead trans arterial chemo embolization

the international arm is the patients embolized with drug eluting bead trans arterial chemo embolization using Hepasphere

Group Type EXPERIMENTAL

HepaSphere Microspheres/Doxorubicin Hydrochloride

Intervention Type DRUG

evaluation the tumor (size, location and pattern of enhancement) ;and ensure portal vein patency; then evaluation of hepatic arterial anatomy, after that we determine the tumor arterial feeders and the arteries that should be avoided during the maneuver.

Selective celiac and superior mesenteric angiograms were performed using 5 Fr. Catheter then superselective angiogram were used microcatheter. then injection of drug-eluting microsphere (25 mg Hepasphere 50-100 micron) loaded with 50 mg doxorubicin solution for 2 hours.

conventional trans arterial chemo embolization

the control arm is the patients embolized with drug eluting bead trans arterial chemo embolization using Lipiodol

Group Type PLACEBO_COMPARATOR

Lipiodol

Intervention Type DRUG

evaluation the tumor (size, location and pattern of enhancement) ;and ensure portal vein patency; then evaluation of hepatic arterial anatomy, after that we determine the tumor arterial feeders and the arteries that should be avoided during the maneuver.

Selective celiac and superior mesenteric angiograms were performed using 5 Fr. Catheter then superselective angiogram were used microcatheter. then injection of prepared mixture of Lipiodol and (Doxorubicin or 5-FU) vary in dosage depend on operator consideration

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

HepaSphere Microspheres/Doxorubicin Hydrochloride

evaluation the tumor (size, location and pattern of enhancement) ;and ensure portal vein patency; then evaluation of hepatic arterial anatomy, after that we determine the tumor arterial feeders and the arteries that should be avoided during the maneuver.

Selective celiac and superior mesenteric angiograms were performed using 5 Fr. Catheter then superselective angiogram were used microcatheter. then injection of drug-eluting microsphere (25 mg Hepasphere 50-100 micron) loaded with 50 mg doxorubicin solution for 2 hours.

Intervention Type DRUG

Lipiodol

evaluation the tumor (size, location and pattern of enhancement) ;and ensure portal vein patency; then evaluation of hepatic arterial anatomy, after that we determine the tumor arterial feeders and the arteries that should be avoided during the maneuver.

Selective celiac and superior mesenteric angiograms were performed using 5 Fr. Catheter then superselective angiogram were used microcatheter. then injection of prepared mixture of Lipiodol and (Doxorubicin or 5-FU) vary in dosage depend on operator consideration

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients must be 18 to 75 years old.
* patients must be diagnosed as primary Hepatocellular carcinoma (HCC) by radiologic imaging revealed angiogenicity pattern .
* All of the patient have Child-Pugh status A or B .
* All of the patient have BCLC stage A or B.
* patients must have adequate renal and liver function accepting the maneuver.
* patients must have adequate coagulation profile (platelets count ≥ 80 000), (prothrombin concentration ≥ 70 %).
* patients must haven't previous history of resection of other ablation (alcohol, radio frequency or micro wave ablation).

Exclusion Criteria

* patients have previous history of resection of other ablation (alcohol, radio frequency or micro wave ablation).
* patients with impaired coagulation profile (platelets count \< 80 000), (prothrombin concentration \< 70 %).
* patients with decompensated liver cell failure having ascites which impedes the maneuver .
* patients with past history of reaction to the drug used in maneuver
* patients with poor image quality.
* patients with lost follow up .

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No